Bio-Techne and Refeyn have launched an integrated workflow combining icIEF fractionation and mass photometry to characterise bispecific antibodies and biosimilars. The four-hour process pairs Bio-Techne's MauriceFlex imaged capillary isoelectric focusing system with Refeyn's TwoMP mass photometry platform. The workflow enables direct correlation of charge heterogeneity with molecular weight and aggregation at single-molecule resolution, requiring only nanogram-level samples. This addresses a key challenge in characterising bispecific antibodies, whose structural complexity often delays development and increases manufacturing risk. The technology allows researchers to analyse aggregation and size within icIEF-resolved charge variants, providing insights previously inaccessible with standalone methods. The integration aims to reduce reliance on multiple tests and accelerate process development for increasingly complex biologics.

Refeyn launches MyMass instrument to simplify sample quality assessment for structural biology. GlobeNewswire Published Mar 18, 2026 Article content Compact, all-in-one mass photometer helps researchers verify sample quality before proceeding to cryo-EM, native MS, BLI, SPR, and other costly experiments Article content OXFORD, United Kingdom, March 18, 2026 (GLOBE NEWSWIRE) - Refeyn, developer of pioneering mass photometry technology, announces the launch of MyMass(TM) mass photometer (MyMassMP), a compact instrument designed to answer a critical research question: Is the sample good enough for further analysis? Article content Structure-based drug design and AI-driven therapeutic development are transforming how new medicines are discovered, but depend on high-quality samples. Structural and biophysical workflows, such as cryo-EM, native mass spectrometry (MS), bio-layer interferometry (BLI), and surface plasmon resonance (SPR), are time-consuming and costly, and poor sample quality remains one of the main reasons they fail. MyMassMP gives researchers a fast, accurate assessment of purity, homogeneity, and oligomerization state in solution before committing to resource-intensive experiments. Article content Advertisement 1 Story continues below Article content Built on the same proven technology as Refeyn's TwoMP mass photometer, which is already trusted across leading structural biology and biotherapeutics labs worldwide, MyMassMP brings this quality check capability into a simpler, self-contained benchtop instrument. Featuring an integrated display and computer for onboard data analysis, and dedicated consumables, it offers an intuitive workflow from sample to result. Article content Top Stories Interested in more newsletters? Browse here. Article content "Structural biology and AI-driven drug discovery are moving fast, but they're only as good as the samples that drive them. MyMass directly addresses that challenge and marks a significant step forward for Refeyn, putting the power of mass photometry within reach of more researchers than ever before," said Gerry Mackay, Refeyn CEO. Article content Fiona Coats, Chief Product and Marketing Officer at Refeyn, said: "In recent years, our users have consistently shown us how valuable mass photometry is for quickly assessing sample quality before committing to more complex experiments. With MyMassMP, we're making this capability even more accessible - empowering researchers to confidently answer a simple but critical question: Are my samples ready?" Article content Advertisement 2 Story continues below Article content About Refeyn Article content Refeyn (www.refeyn.com) specializes in the development, production, and distribution of mass photometry for industry and academia. Enabling accurate mass measurement of single molecules in their native state, and without labels, Refeyn's products deliver crucial analytics faster and use less sample than conventional methods. The company's vision is to accelerate discovery through innovation, empowering the latest scientific breakthroughs in basic research and transforming biotherapeutic development and manufacturing. Article content Advertisement 1 This advertisement has not loaded yet.